Dentin derivative signal (DDS) for differentiation of dental pulp stem cells and dentin-pulp complex regeneration

The DDS composition, derived from demineralized dentin, addresses the limitations of synthetic methods by inducing DPSC differentiation into odontoblasts, effectively regenerating the dentin-pulp complex and preserving pulp vitality, offering a cost-effective and biocompatible solution for dental regeneration.

WO2026234652A1PCT designated stage Publication Date: 2026-11-12HASANZADE SEHER
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/IB2026/054920
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Filing Date
2026-05-18
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing regenerative endodontic methods rely on synthetic or recombinant factors, exogenous cells, and complex molecular inhibitors, which are costly, less biocompatible, and lack the full spectrum of bioactive signals present in natural dentin, limiting their effectiveness and clinical translatability for pulp-dentin regeneration.

Method used

A Dentin Derivative Signal (DDS) composition derived from demineralized dentin, containing a full array of organic proteins, is used to induce dental pulp stem cells (DPSCs) to differentiate into odontoblasts, promoting dentin-pulp complex regeneration without exogenous cells, and is prepared from extracted teeth.

Benefits of technology

The DDS composition effectively induces DPSC differentiation into odontoblasts in vitro and in vivo, regenerating the dentin-pulp complex, preserving pulp vitality and preventing necrosis, and is cost-effective and biocompatible, suitable for direct pulp capping and root canal procedures.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PCTXMLIB-APPB-I000001
    Figure PCTXMLIB-APPB-I000001
  • Figure PCTXMLIB-APPB-I000002
    Figure PCTXMLIB-APPB-I000002
  • Figure PCTXMLIB-APPB-I000003
    Figure PCTXMLIB-APPB-I000003
Patent Text Reader

Abstract

This invention discloses a Dentin Derivative Signal (DDS), a demineralized dentin matrix powder, for use in regenerative dentistry. DDS serves as a natural differentiation factor that induces dental pulp stem cells to differentiate into odontoblasts, both in vitro and in vivo. This differentiation leads to the secretion of a dentin-like tissue and the regeneration of the dentin-pulp complex. Derived from the organic matrix of extracted teeth, DDS is a cost-effective, biocompatible, and accessible alternative to synthetic growth factors. Its application can prevent the need for root canal treatment by enabling the natural regeneration of a dentin bridge, thereby preserving tooth vitality. The invention is applicable in various dental treatments, including direct pulp capping, repair of root perforations, and apexification.
Need to check novelty before this filing date? Find Prior Art

Description

Dentin Derivative Signal (DDS) for Differentiation of Dental Pulp Stem Cells and Dentin-Pulp Complex Regeneration

[0001] The present invention relates generally to the field of regenerative dentistry and tissue engineering. More specifically, it pertains to a novel biological signal derived from natural dentin for inducing the differentiation of dental pulp stem cells (DPSCs) into odontoblasts, thereby promoting the regeneration of the dentin-pulp complex. This invention offers a natural, cost-effective, and accessible alternative to conventional synthetic growth factors and complex regenerative procedures.

[0002] A61C 5 / 50 - A61C 5 / 00 - A61L 27 / 36 - C12N 5 / 0775

[0003] Regenerative endodontics has emerged as a promising alternative to traditional root canal treatments, which involve devitalization of the tooth and replacement of the pulp with inert materials, leading to loss of sensation, vascularity, and increased brittleness. Prior art in this domain has explored various strategies to regenerate the pulp-dentin complex, including the use of stem cells, growth factors, scaffolds, and bioactive molecules. These efforts have demonstrated the potential of DPSCs—multipotent mesenchymal stem cells isolated from dental pulp—to differentiate into odontoblast-like cells capable of producing reparative dentin. However, many existing approaches rely on synthetic or recombinant factors, exogenous cell transplantation, or bone-derived materials, which present limitations in terms of cost, accessibility, immunogenicity, and clinical translatability.

[0004] One notable patent in this area is US Patent Application Publication No. 2014 / 0322672 A1 (published October 30, 2014), titled "Root Canal Filling Material Containing Mesenchymal Stem Cells and Method for Regenerating Dental Tissue Using the Same." This disclosure describes a root canal filling material comprising mesenchymal stem cells (e.g., DPSCs, bone marrow MSCs, or adipose-derived MSCs), extracellular matrix (ECM) proteins (e.g., collagen, gelatin, fibronectin), and chemotactic factors (e.g., stromal cell-derived factor-1 [SDF-1], nerve growth factor [NGF]). The method involves cleaning the root canal, introducing the cell-laden material, and sealing the tooth to promote pulp regeneration, angiogenesis, and dentin-like tissue formation. In vitro and in vivo studies (e.g., in dog and mouse models) showed enhanced cell migration, differentiation, and tissue integration. While this approach effectively induces odontoblast differentiation through a combination of cells and synthetic ECM mimics, it requires exogenous stem cell isolation and transplantation, increasing procedural complexity and potential immunogenicity. Moreover, it does not utilize natural dentin-derived matrices, relying instead on purified or synthetic ECM components, which may lack the full spectrum of bioactive signals present in native dentin.

[0005] Another relevant patent is US Patent No. 8,752,777 B2 (issued June 17, 2014), titled "Method and Pulverizing Apparatus for Preparing Pulverized Product of Extracted Tooth, Demineralized Powder Originated from Extracted Tooth, and Composite of Demineralized Powder and Apatite." This invention focuses on recycling extracted teeth to produce pulverized dentin-enamel mixtures or demineralized dentin powder (DDM) via acid treatment (e.g., HCl or HNO3), retaining collagen and bone morphogenetic proteins (BMPs) for osteoinductive applications. The DDM is combined with apatite to form composites suitable for alveolar bone regeneration, periodontal repair, and dental implants. In vivo testing in nude mice demonstrated osteoinduction without rejection. This patent shares similarities with the present invention in using demineralized dentin from extracted teeth as a natural, BMP-rich material to promote tissue regeneration. However, its primary focus is on bone formation and implant integration rather than targeted odontoblast differentiation in DPSCs for pulp regeneration. It does not address in vitro or in vivo induction of dentin-specific markers (e.g., dentin sialophosphoprotein [DSPP], dentin matrix protein-1 [DMP-1]) or direct application in vital pulp therapy.

[0006] International Patent Publication No. WO 2005 / 016368 A2 (published February 24, 2005), titled "Use of Phosphophoryn for Inducing Biomineralization and Bone Regeneration," discloses the application of phosphophoryn (PP)—a dentin-specific protein—in compositions for promoting osteoblast, cementoblast, and odontoblast differentiation. PP, either native or recombinant, is combined with calcium phosphate ceramics (e.g., hydroxyapatite) or biodegradable polymers (e.g., polycaprolactone) to induce mineralization in periodontal and bone defects. Methods include gene therapy vectors encoding PP or related transcription factors (e.g., RunX2) to enhance osteogenic differentiation, with applications in dentin regeneration and tooth sensitivity treatment. In vitro assays (e.g., alkaline phosphatase activity, alizarin red staining) and animal models confirmed mineral deposition and tissue repair. This prior art highlights the role of individual dentin proteins like PP in odontoblast induction, aligning with the present invention's use of dentin-derived signals. However, it isolates and uses a single protein (PP) rather than the complete organic matrix of demineralized dentin, potentially limiting the synergistic effects of multiple proteins (e.g., collagen types I / III, dentin sialoprotein [DSP], osteocalcin, bone sialoprotein [BSP]). Additionally, it emphasizes bone and periodontal regeneration over pulp-specific applications.

[0007] US Patent Application Publication No. 2021 / 0196743 A1 (published July 1, 2021), titled "Pharmaceutical Composition for Preventing or Treating Dentin-Dental Pulp Disease or Periodontal Disease, Containing LPAR2 Inhibitor," describes a composition using lysophosphatidic acid receptor 2 (LPAR2) inhibitors to promote DPSC differentiation into odontoblasts, cementoblasts, or osteoblasts. The inhibitor modulates signaling pathways (e.g., via RUNX2 and BMP6 expression), enhancing markers like DSPP and DMP1, as shown in real-time PCR and immunostaining. In vivo mouse models demonstrated bone regeneration and vascularization. Formulations include drugs, foods, or beverages for treating pulpitis, necrosis, or periodontal diseases. While this pharmacological approach induces odontoblast differentiation similar to the present invention, it relies on synthetic inhibitors rather than natural dentin matrices, potentially introducing side effects or requiring precise dosing. It does not incorporate DDM as a scaffold, focusing instead on molecular inhibition without physical matrix support.

[0008] US Patent No. 10,667,994 B2 (issued June 2, 2020), titled "Bioactive Dental Restorative Material with Remineralization Properties," discloses a hybrid glass ionomer cement-resin material coated with polydopamine (PDA) for enhanced bioactivity. The composition promotes DPSC viability, adhesion, and odontoblast-like differentiation, with upregulated expression of DSPP and DMP1 via RT-qPCR. In vivo rat studies showed dentin bridge formation. This material supports remineralization and dentin regeneration but uses synthetic PDA-coated particles rather than natural dentin-derived matrices, limiting the breadth of bioactive signals.

[0009] US Patent No. 11,278,474 B2 (issued March 22, 2022), titled "Pulp Regeneration Compositions and Methods of Forming and Using the Same," describes gelatin methacrylate (GelMA) hydrogels encapsulating DPSCs and human umbilical vein endothelial cells (HUVECs) or vascular endothelial growth factor (VEGF) for pulp revascularization. Photo-crosslinking forms vascularized pulp-like tissues in tooth root segments, with in vivo implantation in rats showing cellularized, collagen-rich structures. While effective for pulp regeneration, it employs synthetic hydrogels without natural dentin matrices, relying on exogenous cells and factors.

[0010] International Patent Publication No. WO 2018 / 222761 A1 (published December 6, 2018), titled "Dental Pulp Construct," discloses hydrogel-based constructs (e.g., GelMA) with microchannels for vascularization in root canals. It mentions exposure of dentin matrix components via EDTA treatment to release bioactive factors for stem cell differentiation, including odontoblasts. Co-cultures of stem cells from apical papilla (SCAPs) and HUVECs form vascular networks. However, it primarily uses synthetic hydrogels, with dentin matrix serving as an adjunct rather than the core inductive material.

[0011] International Patent Publication No. WO 2017 / 156102 A1 (published September 14, 2017), titled "Methods and Compositions for Dental Tissue Repair and / or Regeneration," describes triacrylate polymers (e.g., trimethylolpropane triacrylate) that promote DPSC adhesion, proliferation, and differentiation into odontoblasts, with upregulated markers like DSPP and DMP1. In vivo rodent models show reparative dentin formation after pulp injury. This synthetic polymer approach mimics ECM but lacks the natural, multifaceted signals of dentin-derived matrices.

[0012] Chinese Patent No. CN 109504710 B (issued June 22, 2021), titled "Application of KDM4D," discloses the use of histone demethylase KDM4D to promote MSC differentiation into odontoblasts, with overexpression increasing DSPP and DMP1 expression and mineralization. In vivo mouse studies confirm enhanced dentin-like tissue formation. This genetic modulation method does not utilize natural matrices, focusing on epigenetic control.

[0013] Additional prior art includes scientific publications that have influenced the field. For instance, a 2016 study titled "Demineralized Dentin Matrix Induces Odontoblastic Differentiation of Dental Pulp Stem Cells" (Cells Tissues Organs, Vol. 201, pp. 65-76) showed that DDM promotes DPSC adhesion, proliferation, and odontoblast differentiation, with upregulated DSPP and DMP1 expression. Similar findings appear in reviews like "Physiologic Dentin Regeneration: Its Past, Present, and Future Perspectives" (Frontiers in Physiology, 2023), which discuss DDM's role in vital pulp therapy. These studies validate DDM's efficacy but often focus on in vitro or animal models without optimized preparation methods for clinical scalability.

[0014] Furthermore, demineralized freeze-dried bone allograft (DFDBA), a commercially available product (e.g., from companies like Osteogenics Biomedical), uses demineralized bone for alveolar ridge augmentation and implant support. While analogous in concept—exposing collagen and growth factors for osteoinduction—DFDBA is bone-derived and lacks dentin-specific proteins essential for odontoblast induction, making it less suitable for pulp-dentin regeneration.

[0015] Limitations of Prior Art and Advantages of the Present Invention

[0016] Despite these advances, prior art suffers from several drawbacks: (1) reliance on synthetic or recombinant factors (e.g., LPAR2 inhibitors, triacrylate polymers, PDA coatings, or hydrogels like GelMA), which may be costly, less biocompatible, or prone to variability; (2) need for exogenous stem cells, gene therapy, or complex molecular inhibitors, increasing risks of rejection or ethical concerns; (3) focus on single proteins (e.g., phosphophoryn) or ECM mimics rather than the complete dentin matrix, potentially missing synergistic effects; (4) emphasis on bone or periodontal regeneration over pulp-specific applications; and (5) limited use of accessible, autologous materials from waste teeth, leading to higher costs and reduced translatability.

[0017] The present invention overcomes these limitations by utilizing DDS, a powder derived from demineralized dentin of extracted teeth, containing the full array of organic dentin proteins (e.g., collagen types I / III, DSP, dentin phosphoprotein [DPP], DMP1, osteonectin, osteocalcin, BSP, osteopontin). This natural signal induces DPSC differentiation into odontoblasts both in vitro (e.g., via alizarin red staining and DSPP / DMP1 expression) and in vivo, regenerating the pulp-dentin complex without exogenous cells. DDS is biocompatible, cost-effective (sourced from discarded teeth), and easily prepared as a powder mixed with physiological saline for direct application in pulp capping or root canal procedures. It preserves pulp vitality, prevents necrosis, and extends to applications like root perforation repair, immature apex maturation, and trauma recovery. Unlike bone-derived materials, DDS is dentin-specific, ensuring targeted odontoblast induction. Preclinical data, [Pic. 1] to [Pic. 3] demonstrate time-dependent increases in DSPP expression and dentin formation, supporting its superiority for comprehensive pulp-dentin regeneration.

[0018] In summary, while prior art provides foundational insights into stem cell-based dental regeneration, the present invention represents a novel, natural, and practical advancement by harnessing the complete demineralized dentin matrix to achieve efficient, predictable, and clinically viable outcomes.

[0019] The invention provides a Dentin Derivative Signal (DDS) composition comprising the complete organic matrix of demineralized dentin, including proteins such as Collagen Type I, Collagen Type III, Dentin Sialoprotein (DSP), Dentin Phosphoprotein (DPP), Dentin Glycoprotein (DGP), and Dentin Matrix Protein-1 (DMP1). DDS acts as a potent and natural differentiation factor. When placed in contact with dental pulp stem cells, either in vitro or in vivo, it effectively induces their differentiation into functional odontoblasts. These differentiated cells subsequently secrete a dentin-like tissue, facilitating the regeneration of a dentin bridge. This process can prevent the need for conventional root canal treatment by protecting the dental pulp from bacterial infection and restoring the damaged dentin layer. The invention is further directed to methods of preparing the DDS powder from extracted teeth and its use in various dental and endodontic regenerative therapies.

[0020] The standard treatment for deep carious lesions reaching the dental pulp is root canal therapy. This procedure involves the complete removal of the pulp tissue, leading to a loss of tooth vitality, sensation, and blood supply, ultimately resulting in a brittle, non-vital tooth. While regenerative endodontics aims to preserve pulp vitality, current approaches face significant limitations.

[0021] Previous studies have utilized synthetic growth factors or single proteins (e.g., BMP-2, DMP-1) to induce differentiation. However, these are often expensive, not fully representative of the natural dentinogenic environment, and may raise biocompatibility concerns. Other strategies involve the complex combination of stem cells, scaffolds, and growth factors, which are technically challenging, difficult to standardize, and not cost-effective for routine clinical practice. There is a clear gap for a simple, natural, and economically viable signal that can harness the body's own regenerative potential by utilizing the complete set of proteins naturally present in dentin to effectively guide stem cell differentiation and dentin regeneration.Solution of Problem

[0022] 1. Composition and Source Material

[0023] The core of the invention is the DDS composition, which is a demineralized, sterilized powder obtained from the dentin layer of human teeth, typically those that are extracted and would otherwise be discarded. The critical innovation lies in utilizing the entire native protein profile of the dentin matrix, rather than a single recombinant or synthetic growth factor. This full-complement matrix provides a more physiologically accurate and potent signal for odontogenic differentiation.

[0024] The composition comprises a multitude of native dentin matrix proteins, including but not limited to:

[0025] Structural Proteins: Collagen Type I, Collagen Type III.

[0026] Non-Collagenous Proteins (NCPs) Specific to Dentin:

[0027] Dentin Sialoprotein (DSP)

[0028] Dentin Phosphoprotein (DPP) / Phosphophoryn

[0029] Dentin Glycoprotein (DGP)

[0030] Dentin Matrix Protein-1 (DMP1)

[0031] Other Matrix Proteins: Osteonectin, Osteocalcin, Bone Sialoprotein (BSP), Osteopontin, Matrix Extracellular Phosphoglycoprotein (MEPE).

[0032] The DDS is characterized by being substantially free of water and inorganic mineral components, such as calcium and hydroxyapatite crystals, which are removed during the demineralization process. The final product is a biocompatible, off-white powder that can be readily reconstituted with a physiological solution (e.g., saline) to form a workable paste for clinical application.

[0033] 2. Method of Preparation

[0034] Referring to the schematic overview in, the preparation of DDS involves a precise, multi-step protocol:

[0035] Step 1: Collection and Cleaning. Extracted human teeth are collected and thoroughly cleaned. They are stored in a container with physiological saline containing a small amount of sodium hypochlorite to maintain sterility.

[0036] Step 2: Removal of Non-Dentin Tissues. The enamel and cementum layers are meticulously removed using, for example, a diamond fissure bur (e.g., 008) with water spray cooling. The tooth is then sectioned, and the pulp tissue is completely extirpated using an excavator, leaving behind the pure dentin layer.

[0037] Step 3: Processing and Demineralization. The remaining dentin block is segmented into small pieces (e.g., 1x1 mm) to increase surface area. These pieces are then subjected to demineralization by immersion in a solution of acetic acid for a period of approximately 14 days. This process dissolves the mineral content, leaving behind the insoluble organic matrix, which takes on a gelatinous consistency.

[0038] Step 4: Powder Formation and Sterilization. The resulting demineralized dentin matrix (DDM) gel is then processed into a fine, homogeneous powder using appropriate lyophilization (freeze-drying) or desiccation techniques. The final powder is sterilized (e.g., by gamma irradiation or ethylene oxide) to ensure it is safe for clinical use.

[0039] 3. Mechanism of Action and Biological Efficacy

[0040] The invention's mechanism is based on providing a native biological scaffold and signaling cocktail that directly instructs DPSCs to commit to the odontoblast lineage.

[0041] In Vitro Differentiation Protocol: As detailed in the original disclosure, human DPSCs (hDPSCs) are isolated, expanded, and purified through serial passaging (typically up to passage 4). These cells are then seeded at a density of, for example, 10000 cells / cm² in culture plates. Upon reaching 70-80% confluence, the standard growth medium is replaced with a differentiation-inducing medium. Crucially, the DDS powder is introduced into this culture environment. The cells are cultured in contact with DDS for a period of up to 10 days, with the medium being changed every 2-3 days.

[0042] Confirmation of Differentiation: The successful differentiation is confirmed through multiple analytical methods:

[0043] Cytochemical Staining: Alizarin Red staining (ICC) is used to detect calcium deposition and mineralized nodule formation, a hallmark of odontoblast activity.

[0044] Immunocytochemistry (ICC): As shown in [Pic. 1], staining for specific markers like Dentin Sialophosphoprotein (DSPP) confirms the expression of dentin-specific proteins. Nuclei are counterstained with DAPI. The co-localization and increasing intensity of DSPP signal over time, as quantified in [Pic. 3], provide direct evidence of successful differentiation. Staining for DMP-1 further validates the odontoblastic phenotype.

[0045] Cell Viability Assays: Tests such as the MTT assay confirm that the DDS composition supports high cell viability and proliferation, indicating its excellent biocompatibility.

[0046] The data demonstrates that with increased time of exposure to DDS (e.g., 3, 7, and 10 days), there is a corresponding significant increase in the expression of odontogenic markers like DSPP compared to negative control groups, proving the temporal efficacy of the DDS signal.

[0047] 4. Clinical Application and Use

[0048] The DDS composition is designed for straightforward clinical integration. The sterile DDS powder is mixed with a sterile physiological solution at the point of care to create a malleable paste. This paste can then be applied directly to the site of need, such as:

[0049] A direct pulpal exposure after caries removal.

[0050] The site of a root perforation.

[0051] The apex of an immature, non-vital tooth (apexogenesis).

[0052] The floor of a pulpotomy.

[0053] Upon application, the DDS factor elutes its native proteins into the local microenvironment. This recruits resident DPSCs and provides the necessary morphogenetic signals to direct their differentiation into odontoblasts. These newly formed odontoblasts then secrete a reparative dentin matrix, effectively forming a "dentin bridge" that seals the exposure and regenerates the lost hard tissue. This process preserves pulp vitality, eliminating the need for traditional root canal therapy.Advantage Effects of the Invention

[0054] • Utilizes a natural, biologically relevant signal instead of synthetic growth factors.

[0055] • Excellent biocompatibility and no expected side effects.

[0056] • Eliminates the need for allogeneic stem cells by stimulating the patient's own (autologous) DPSCs.

[0057] • Promotes regeneration of a dentin bridge, preserving pulp vitality and preventing the need for root canal treatment.

[0058] • Highly accessible and cost-effective, as it is derived from otherwise discarded extracted teeth.

[0059] • Applicable in direct pulp capping as a superior alternative to conventional materials like calcium hydroxide.

[0060] • Enables dentin regeneration in cases of root perforations, furcation perforations, and immature roots with open apices.

[0061] • Capable of regenerating the entire dentin-pulp complex, including connective tissue, blood vessels, and nerves.

[0062] • The differentiation process is predictable, controllable, and yields cells with a stable morphology similar to natural odontoblasts.

[0063] • Unlike prior art relying on isolated proteins (e.g., phosphophoryn in WO 2005 / 016368), DDS leverages the synergistic interplay of the full dentin organic matrix, resulting in more predictable and robust odontoblast differentiation, as evidenced by time-dependent DSPP upregulation (up to 100% at 10 days vs. 0% in controls).

[0064] Shows a schematic of the claimed process.

[0065] Shows a schematic flowchart illustrating the process of differentiating dental pulp stem cells into odontoblasts and producing dentin tissue using the Dentin Derivative Signal (DDS) composition.

[0066] 1) Isolated Dental Pulp Stem Cells: Represents the initial population of stem cells harvested from the dental pulp.

[0067] 2) DDS (Dentin Derivative Signal) Composition: Represents the demineralized dentin matrix powder, the key inventive material.

[0068] 3) Differentiated Odontoblasts: Represents the target cells after successful differentiation, characterized by their specific morphology.

[0069] 4) Extracted Tooth: Represents the source material for both the stem cells (pulp) and the DDS composition (dentin).

[0070] 5)Dental Pulp: The soft tissue inside the tooth from which the stem cells are derived.Examples

[0071] Example 1: Clinical Application for Direct Pulp Capping

[0072] A clinical scenario is described wherein a deep carious lesion in a permanent molar results in a small, pinpoint exposure of the dental pulp (less than 1 mm in diameter) after complete caries excavation. The area is isolated using a rubber dam and disinfected with a mild antiseptic such as 2.5% sodium hypochlorite, followed by irrigation with sterile saline.

[0073] The Dentin Derivative Signal (DDS) composition is prepared for application by mixing the sterile DDS powder with a sterile physiological saline solution at a ratio of approximately 2:1 (powder to liquid, w / v) to create a cohesive, workable paste.

[0074] Approximately 1-2 mm of the DDS paste is applied directly over the pulpal exposure site, ensuring direct and gentle contact with the exposed pulp tissue. A layer of a biocompatible, non-setting calcium hydroxide cement or a glass ionomer base material is then placed over the DDS to provide a seal and mechanical support. The tooth is subsequently restored with a definitive restoration, such as a composite resin.

[0075] Clinical and radiographic follow-up at 3, 6, and 12 months demonstrates the absence of symptoms (pain, sensitivity to percussion), absence of periapical pathology on radiograph, and evidence of a continuous dentin bridge formation at the exposure site. This confirms the successful outcome of the vital pulp therapy, preserving tooth vitality and obviating the need for root canal treatment.

[0076] Example 2: Application for Root Perforation Repair

[0077] A scenario is described involving an iatrogenic furcation perforation (approximately 1.5 mm in diameter) during access cavity preparation. The perforation site is located, and hemostasis is achieved.

[0078] The DDS paste, prepared as in Example 1, is carefully packed into the perforation defect using a dedicated delivery system, such as a Messing gun or an amalgam carrier, ensuring the material is condensed to fill the defect completely and establish contact with the surrounding periodontal tissues.

[0079] The access cavity is then sealed. Follow-up radiographs at 6 months show evidence of hard tissue repair at the perforation site, sealing the communication between the root canal system and the periodontium, as indicated by the re-establishment of the periodontal ligament space and the absence of a radiolucent lesion.

[0080] [Pic. 1] Immunocytochemistry (ICC) images showing the expression and localization of markers DSPP (Dentin Sialophosphoprotein) and DAPI (nuclear stain) in the studied groups over time.

[0081] Panel A (Negative Control): Images showing minimal to no expression of the DSPP marker (likely a faint red signal), with only the blue DAPI-stained nuclei visible.

[0082] Panel B (Day 3 Group): Images showing initial, low-level expression of the DSPP marker (punctate or light red signal) co-localizing with the cell nuclei.

[0083] Panel C (Day 7 Group): Images showing increased expression and distribution of the DSPP marker (stronger, more widespread red signal).

[0084] Panel D (Day 10 Group): Images showing intense and extensive expression of the DSPP marker (bright, confluent red signal), indicating high levels of dentin matrix production.

[0085] Merge: For each panel, a combined image showing the overlay of the DSPP (red) and DAPI (blue) channels, demonstrating that the marker expression is occurring within the cells.

[0086] [Pic. 1]

[0087]

[0088] [Pic. 2] An schematic generated from [Pic. 1] for more clarity.

[0089] [Pic. 2]

[0090]

[0091] [Pic. 3] A graph quantifying the percentage expression of the DSPP marker in dental pulp mesenchymal stem cells across the 3-day, 7-day, and 10-day test groups, compared to a negative control group.

[0092] Y-axis: Labeled as "DSPP Expression (%)" or "Relative DSPP Expression".

[0093] X-axis: Labeled as "Study Groups", with four distinct bars:

[0094] Negative Control: A bar showing a value at or near 0%.

[0095] Day 3: A bar showing a low but measurable percentage of expression.

[0096] Day 7: A bar showing a significantly higher percentage than Day 3.

[0097] Day 10: A bar showing the highest percentage of expression among all groups.

[0098] A legend or annotation on the graph should indicate that the data demonstrates a time-dependent increase in DSPP expression upon treatment with the DDS composition.

[0099] [Pic. 3]

[0100]

[0101] This invention has significant industrial application in the fields of restorative dentistry and regenerative endodontics. It is directly applicable for use in:

[0102] Dental clinics for procedures like direct pulp capping and treatment of deep caries.

[0103] Endodontic specialist practices for managing traumatic injuries, root perforations, and apexogenesis.

[0104] The biomedical industry for the production of novel, natural biomaterials for tissue regeneration.

[0105] Veterinary dentistry for treating dental diseases in companion animals.

[0106] Organizations such as dental product manufacturers, biomedical research institutions, and university dental schools would have a strong interest in this technology.

Claims

A biocompatible composition for inducing odontogenic differentiation, comprising: a demineralized dentin matrix (DDM) powder, wherein said DDM powder consists of the organic matrix of natural dentin, and wherein said organic matrix comprises a native combination of dentin-specific non-collagenous proteins.The composition of claim 1, wherein the dentin-specific non-collagenous proteins are selected from the group consisting of: Dentin Sialoprotein (DSP), Dentin Phosphoprotein (DPP), Dentin Glycoprotein (DGP), Dentin Matrix Protein-1 (DMP1), and combinations thereof.The composition of claim 1 or 2, wherein the organic matrix further comprises Collagen Type I and Collagen Type III.The composition of any one of claims 1 to 3, wherein the DDM powder is sterilized and is configured to be mixed with a physiological carrier to form a paste for clinical application.A method of preparing a biocompatible composition for inducing odontogenic differentiation, the method comprising the steps of: a) obtaining a dentin sample from an extracted tooth; b) demineralizing the dentin sample to substantially remove inorganic mineral content, thereby yielding a demineralized dentin matrix (DDM); and c) processing the DDM into a powder.The method of claim 5, wherein step (b) of demineralizing comprises treating the dentin sample with an acid for a period sufficient to achieve demineralization.The method of claim 5 or 6, further comprising a step of sterilizing the powder after step (c).A method for in vitro differentiation of dental pulp stem cells (DPSCs) into odontoblasts, the method comprising: culturing a population of DPSCs in a culture medium in direct contact with an effective amount of the composition of any one of claims 1 to 4, thereby inducing said DPSCs to differentiate into odontoblasts.The method of claim 8, wherein differentiation of the DPSCs into odontoblasts is characterized by increased expression of Dentin Sialophosphoprotein (DSPP) compared to a control culture not in contact with the composition.A method for regenerating dentin tissue at a site in a tooth of a subject in need thereof, the method comprising: applying an effective amount of the composition of any one of claims 1 to 4 to the site, wherein the composition induces the formation of a reparative dentin bridge.The method of claim 10, wherein the site is selected from the group consisting of: a pulpal exposure, a site of caries removal, a root perforation, a furcation perforation, and the apex of an immature tooth.The method of claim 10 or 11, wherein the composition induces the differentiation of endogenous dental pulp stem cells into odontoblasts at the site.Use of the composition of any one of claims 1 to 4 in the manufacture of a medicament for regenerating dentin tissue in a damaged tooth.Use of the composition of any one of claims 1 to 4 as a direct pulp capping agent.